Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (1996)
  2. Solid Tumor Oncology Division (1625)
  3. GSK Faculty (766)
  4. Survivorship Research (640)
  5. Population Sciences Research Program (616)
  6. Epidemiology and Biostatistics (466)
  7. Department of Pathology and Laboratory Medicine (416)
  8. Gastrointestinal Oncology Service (387)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1996)
  2. Solid Tumor Oncology Division (1625)
  3. GSK Faculty (766)
  4. Survivorship Research (640)
  5. Population Sciences Research Program (616)
  6. Epidemiology and Biostatistics (466)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: A NRG Oncology-Gynecologic Oncology Group study
    Meeting Abstract

    Tewari, K. S.; Sill, M. W.; Penson, R. T.; Huang, H.; Ramondetta, L. M.; Landrum, L. M.; Oaknin, A.; Reid, T. J.; Leitao, M. M.; Monk, B. J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Phase IB/II study of LEE011 (CDK4/6 inhibitor) and LGX818 (BRAF Iinhibitor) in BRAF-mutant melanoma
    Meeting Abstract

    Taylor, M.; Sosman, J.; Gonzalez, R.; Carlino, M. S.; Kittaneh, M.; Lolkema, M. P.; Miller, W.; Marino, A.; Zhang, V.; Bhansali, S. G.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (MCRPC) patients (pts) without prior chemotherapy
    Meeting Abstract

    Ryan, C. J.; Smith, M. R.; Fizazi, K.; Miller, K.; Mulders, P.; Sternberg, C. N.; Saad, F.; Griffin, T.; De Porre, P.; Park, Y. C.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro; MK-3475) for advanced melanoma (MEL): Randomized comparison of two dosing schedules
    Meeting Abstract

    Robert, C.; Joshua, A. M.; Weber, J. S.; Ribas, A.; Hodi, F. S.; Kefford, R. F.; Daud, A.; Wolchok, J. D.; Hwu, W. J.; Gangadhar, T. C.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Phase 1B trial of anti-notch 2/3 antibody OMP-59R5 in combination with etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC): The pinnacle study
    Meeting Abstract

    Pietanza, M. C.; Spira, A.; Jotte, R.; Gadgeel, S.; Mita, A.; Liu, S.; Gluck, W. L.; Kalemkerian, G. P.; Chiang, A.; Hart, L.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Disease-free survival (DFS) in the lapatinib alone arm and expanded results of the phase III ALTTO trial (BIG 2-06; NCCTG (alliance) N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC)
    Meeting Abstract

    Perez, E. A.; Holmes, E.; de Azambuja, E.; Dueck, A.; Baselga, J.; Viale, G.; Zujewski, J. A.; Goldhirsch, A.; Crescenzo, R.; Pritchard, K.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Randomized, dose-ranging phase II trial of nivolumab for metastatic renal cell carcinoma (MRCC)
    Meeting Abstract

    Motzer, R. J.; Rini, B. I.; McDermott, D. F.; Redman, B.; Kuzel, T.; Harrison, M. R.; Vaishampayan, U. N.; Drabkin, H.; George, S.; Logan, T.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist selinexor (KPT-330) in patients (pts) with platinum resistant/refractory ovarian cancer (OVCA)
    Meeting Abstract

    Martignetti, J.; Razak, A. R. A.; Chen, Y.; Gabrail, N. Y.; Gerecitano, J. F.; Camacho, C.; Pereira, E.; Evans, B.; Dottino, P.; McCauley, D.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes for 61 patients with metastatic pulmonary carcinoids
    Meeting Abstract

    Litvak, A.; Iyriboz, T.; Zakowski, M.; Woo, K.; Krug, L.; Rudin, C.; Pietanza, M.
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis program (MAP) at Memorial Sloan Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Krug, L. M.; Pietanza, M. C.; Varghese, A. M.; Won, H.; Wang, L.; Rekhtman, N.; Travis, W. D.; Litvak, A.; Paik, P. K.; Riely, G. J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save